El A commercial action plan to promote the use of market-regulating medicines in the National Health System: biosimilar medicines and generic medicines, which CF exclusively advanced, includes, by agreement between Ministry of Health and autonomies, the development of policies for the use of biosimilar medicines, agreed upon by the Pharmacy and Therapeutics Commissions, "that promote both the prescription of biosimilar medicines at the beginning of treatment that require biological treatment and the promotion of interchangeability of medicines under the acceptance of the patient.

READ MORE